

Journal of Visualized Experiments

Optimization of Radiochemical Reactions Using Droplet Arrays

--Manuscript Draft--

Article Type:	Invited Methods Collection - JoVE Produced Video
Manuscript Number:	JoVE62056R1
Full Title:	Optimization of Radiochemical Reactions Using Droplet Arrays
Corresponding Author:	R. Michael van Dam University of California Los Angeles Los Angeles, CA UNITED STATES
Corresponding Author's Institution:	University of California Los Angeles
Corresponding Author E-Mail:	mvandam@mednet.ucla.edu
Order of Authors:	R. Michael van Dam Alejandra Rios Travis Holloway Jia Wang R. Michael van Dam
Additional Information:	
Question	Response
Please specify the section of the submitted manuscript.	Chemistry
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Los Angeles, CA, USA
Please confirm that you have read and agree to the terms and conditions of the author license agreement that applies below:	I agree to the Author License Agreement
Please provide any comments to the journal here.	

TITLE:

Optimization of Radiochemical Reactions Using Droplet Arrays

AUTHORS AND AFFILIATIONS:

Alejandra Rios^{1,2}, Travis S. Holloway^{2,3}, Jia Wang^{2,4}, R. Michael van Dam^{1,2,3,4}

¹Physics and Biology in Medicine Interdepartmental Graduate Program, University of California Los Angeles (UCLA)

²Crump Institute of Molecular Imaging, UCLA

³Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, UCLA

⁴Department of Bioengineering, UCLA

KEYWORDS:

high-throughput, radiochemistry, synthesis optimization, microfluidics, nanomole chemistry, green chemistry

SUMMARY:

This method describes the use of a novel high-throughput methodology, based on droplet chemical reactions, for the rapid and economical optimization of radiopharmaceuticals using nanomole amounts of reagents.

ABSTRACT:

Current automated radiosynthesizers are designed to produce large clinical batches of radiopharmaceuticals. They are not well suited for reaction optimization or novel radiopharmaceutical development since each data point involves significant reagent consumption, and contamination of the apparatus requires time for radioactive decay before the next use. To address these limitations, a platform for performing arrays of miniature droplet-based reactions in parallel, each confined within a surface-tension trap on a patterned polytetrafluoroethylene-coated silicon “chip”, was developed. These chips enable rapid and convenient studies of reaction parameters including reagent concentrations, reaction solvent, reaction temperature and time. This platform permits the completion of hundreds of reactions in a few days with minimal reagent consumption, instead of taking months using a conventional radiosynthesizer.

INTRODUCTION:

Positron-emission tomography (PET) radiopharmaceuticals are widely used as research tools to monitor specific in vivo biochemical processes and study diseases, and for the development of new drugs and therapies. Moreover, PET is a critical tool for diagnosing or staging disease and monitoring a patient’s response to therapy^{1–3}. Due to the short half-life of PET radioisotopes (e.g., 110 min for fluorine-18-labeled radiopharmaceuticals) and radiation hazard, these compounds are prepared using specialized automated systems operating behind radiation shielding and must be prepared just before use.

Current systems used to synthesize radiopharmaceuticals are designed to produce large batches

that are divided up into many individual doses to share the production cost. While current systems are suitable for the production of widely used radiotracers like [^{18}F]FDG (because multiple patient scans and research experiments can be scheduled in a single day), these systems can be wasteful for the production of novel radiotracers during early-stage development, or less commonly used radiotracers. Volumes that conventional systems use are typically in the 1-5 mL range, and the reactions require precursor amounts in the 1-10 mg range. Furthermore, using conventional radiosynthesizers is generally cumbersome during optimization studies since the apparatus becomes contaminated after use and the user must wait for radioactivity to decay before performing the next experiment. Aside from equipment cost, the cost of the radioisotope and reagents can, therefore, become very substantial for studies requiring production of multiple batches. This can occur, for example, during the optimization of synthesis protocols for novel radiotracers to achieve sufficient yield and reliability for initial in vivo imaging studies.

Microfluidic technologies have been increasingly used in radiochemistry to capitalize on several advantages over conventional systems⁴⁻⁶. Microfluidic platforms, including those based on 1-10 μL reaction volumes⁷⁻⁹, have shown a significant reduction of reagent volumes and consumption of expensive precursors, as well as short reaction times. These reductions lead to lower costs, faster heating and evaporation steps, shorter and more straightforward downstream purification, an overall “greener” chemistry process¹⁰, and higher molar activity of the produced radiotracers¹¹. These improvements make it more practical to perform more detailed optimization studies by lowering the reagent cost of each synthesis. Further benefits can be achieved by performing multiple experiments from a single batch of radioisotope in a single day. For example, microfluidic flow chemistry radiosynthesizers operating in “discovery mode” can sequentially perform dozens of reactions, each using only 10s of μL reaction volume¹².

Inspired by these advantages, a multi-reaction droplet array chip in which microvolume reactions are confined to an array of surface-tension traps on a silicon surface, created using a patterned Teflon coating, was developed. These chips enable multiple reactions at the 1-20 μL scale to be performed simultaneously, opening the possibility to explore 10s of different reaction conditions per day, each with multiple replicates. In this paper, the utility of this new high-throughput approach for performing rapid and low-cost radiochemistry optimizations is demonstrated. Using multi-reaction droplet chips allows for convenient exploration of the impact of reagent concentrations and reaction solvent, and the use of multiple chips could enable the study of reaction temperature and time, all while consuming very low amounts of precursor.

PROTOCOL:

CAUTION: This protocol involves the handling of radioactive materials. Experiments should not be undertaken without the necessary training and personal protective equipment and approval from the radiation safety office at your organization. Experiments should be performed behind radiation shielding, preferably in a ventilated hot cell

1. Fabrication of multi-reaction chips

NOTE: Batches of multi-reaction microdroplet chips are fabricated from 4" silicon wafers using standard photolithography techniques, as previously described¹⁰ (Figure 1). This procedure will produce 7 chips each with 4 x 4 array of reaction sites.

1.1. Place silicon wafer on the spin-coater chuck, ensuring that it is centered. Deposit 3 mL of polytetrafluoroethylene solution at the center of the wafer with a transfer pipette and coat wafer at a 1000 rpm for 30 s (500 rpm/s ramp).

1.2. To solidify the coating, place the wafer on a 160 °C hotplate for 10 min and then transfer to a 245 °C hotplate for 10 min.

1.3. Anneal the coating in a high-temperature oven at 340 °C for 3.5 h under nitrogen atmosphere, followed by cooling to 70 °C at a 10 °C/min ramp.

1.4. Place the silicon wafer on the spin-coater chuck, ensuring that it is centered. Pour 2 mL of positive photoresist at the center of the wafer using a transfer pipette, and then perform coating at 3000 rpm for 30 s (1000 rpm/s ramp).

1.5. Solidify the photoresist by performing a soft bake of the wafer on a 115 °C hotplate for 3 min.

1.6. Install the wafer and photomask in a mask aligner and perform a 14 s exposure at 12 mW/cm² lamp intensity and 356 nm wavelength in hard contact mode. This step uses a transparency mask containing the negative final polytetrafluoroethylene pattern, i.e., a 4" diameter pattern of 4 copies of the 16-reaction chip, with reaction sites transparent and all other regions in opaque color.

1.7. Submerge the wafer using 20 mL of photoresist developer solution in a glass container for 3 min with slight agitation to develop the exposed pattern.

1.8. Rinse away the developing solution by submerging the wafer in a glass container with 20 mL of DI water for 3 min with slight agitation. Dry the wafer with a nitrogen gun.

1.9. Remove the exposed polytetrafluoroethylene regions via reactive-ion etching (RIE) with oxygen plasma under the following conditions: 30 s exposure, 100 mTorr pressure, 200 W power, and 50 sccm oxygen flow.

1.10. Dice the wafer into individual chips (7 total per wafer) using a silicon wafer cutter.

1.11. Submerge each chip in acetone for 1 min to remove the photoresist, then isopropanol for 1 min. Finally, dry each chip with a nitrogen gun.

1.12. Place dry chips in a glass container and cover with aluminum foil for storage until use.

2. Planning of the optimization study

NOTE: In this protocol, synthesis of the radiopharmaceutical [^{18}F]fallypride is used as an example to illustrate high-throughput optimization (**Figure 2**). With a single chip, 16 simultaneous reactions can be performed, for example, with varied precursor concentration (8 different concentrations, $n=2$ replicates each). The conditions are mapped to reaction sites in **Figure 3A**. Adjustments can be made to this protocol to optimize other reaction parameters (e.g. reaction solvent, reaction volume, amount of TBAHCO_3 , etc.) or other radiopharmaceuticals.

2.1. Select the reaction parameter(s) to be varied, the specific values to be used, and the number of replicates.

2.2. Compute the number of chips needed to perform the experiment.

2.3. For each chip, prepare a map of which reaction conditions will be used at each reaction site to assist with reagent preparation and performing the droplet reactions.

3. Preparation of reagents and materials for optimizing the radiosynthesis of [^{18}F]fallypride

NOTE: The droplet-based radiosynthesis of [^{18}F]fallypride (**Figure 2**) begins with the addition of [^{18}F]fluoride and phase transfer catalyst (TBAHCO_3) to the reaction site, followed by heating to evaporate water and leave a dried residue. Next, a droplet of precursor (tosyl-fallypride) in reaction solvent (thexyl alcohol and acetonitrile) is added and heated to perform the radiofluorination reaction. Finally, the crude product is collected from the chip for analysis. The reagent preparation and synthesis procedures should be adapted if performing optimization of a different tracer.

3.1. Prepare a 30 μL stock solution of precursor (tosyl-fallypride) in the reaction solvent with the maximum concentration to be explored (77 mM). Ensure that the volume is enough to perform the planned experiment. In this example optimization, $\sim 30 \mu\text{L}$ is sufficient.

3.2. Prepare a stock solution of the reaction solvent, consisting of thexyl alcohol and acetonitrile in a 1:1 by volume mixture. Ensure that the volume is enough to create the planned dilution series. In this example optimization, $\sim 30 \mu\text{L}$ is sufficient.

3.3. From the precursor stock solution and reaction solvent, perform 2x serial dilutions to prepare the different concentrations of the precursor solution. Ensure that the volume of each dilution is enough to perform the desired number of replicates for each condition. In this example optimization, $\sim 15 \mu\text{L}$ of each concentration is sufficient.

3.4. Prepare microcentrifuge tubes to collect each crude reaction product using a permanent marker to label each tube with a unique number. Ensure that the total number of microcentrifuge tubes matches the number of conditions multiplied by the number of replicates ($8 \times 2 = 16$).

3.5. Prepare a stock of collection solution (10 mL) comprising 9:1 methanol:DI water (v/v). Aliquot 50 μ L into each of 16 additional labeled microcentrifuge tubes (one per reaction site on the chip).

3.6. Prepare a [^{18}F]fluoride stock solution in a 500 μ L microcentrifuge tube by mixing [^{18}F]fluoride/[^{18}O]H₂O (~260 MBq [7 mCi]) with 75 mM TBAHCO₃ solution (56 μ L) and diluting with DI water up to 140 μ L. 8 μ L of this solution will be loaded to each reaction site (containing ~15 MBq [0.40 mCi] of activity, and 240 nmol of TBAHCO₃).

4. **Parallel synthesis of [^{18}F]fallypride with different precursor concentrations**

NOTE: The chip is operated atop a heating platform (constructed as previously described¹³) consisting of a 25 mm x 25 mm ceramic heater, controlled using an on-off temperature controller using the internal thermocouple signal for feedback. Heater surface temperatures were calibrated using thermal imaging. If such a platform is not available, a pair of hot plates can be used (one at 105 °C and one at 110 °C).

4.1. Load [^{18}F]fluoride stock solution (with phase transfer catalyst).

4.1.1. Using a micropipette, load an 8 μ L droplet of [^{18}F]fluoride stock solution on the first reaction spot of a multi-reaction chip. Measure the activity of the chip by placing it in a dose calibrator and record the time at which measurement is conducted.

4.2. Remove the chip from dose calibrator and then load an 8 μ L droplet of [^{18}F]fluoride stock solution on the second reaction spot. Measure the activity on the chip by placing it once again in the dose calibrator and record the time at which measurement is conducted.

4.3. Repeat for all other reaction sites on the chip.

4.4. Calculate the activity loaded per reaction spot by taking the activity measurement after loading the radioisotope and subtracting the previous measurement (decay-corrected) before that site was loaded.

4.2. Align the multi-reaction chip on the heater.

4.2.1. Add a thin layer of thermal paste on top of the ceramic heater.

4.2.2. Carefully place the chip on top of the heater using tweezers to avoid the spill of the droplets, aligning the reference corner of the chip with the reference corner of the heater (as shown in **Figure 3B**). The chip will overhang the heater by a small amount.

4.3. Dry the [^{18}F]fluoride and phase transfer catalyst.

4.3.1. Heat the chip for 1 min by setting the heater to 105 °C in the control program to evaporate the droplets to dryness leaving a dried residue of [¹⁸F]fluoride and TBHACO₃. After 1 min, cool the chip by setting the heater to 30 °C and turning on the cooling fan with the control program.

4.4. Add the precursor solution.

4.4.1. Using a micropipette, add a 6 µL solution of fallypride precursor on top of the dried residue on the first reaction site.

4.4.2. Repeat for all other reaction sites on the chip. Use the optimization plan to determine which concentration of the dilution series is used for each reaction site.

4.5. Perform fluorination reaction.

4.5.1. Heat each chip to 110 °C for 7 min using the control program to perform radiofluorination reaction. Afterwards, cool the chip by setting the heater to 30 °C and turning on cooling fan with the control program.

4.6. Collect the crude products from the reaction sites.

4.6.1. Collect the crude product at the first reaction site by adding 10 µL of collection solution from the designated microcentrifuge tube via micropipette. After waiting for 5 s, use the micropipette (with the same tip installed) to aspirate the diluted crude product and transfer to its corresponding labeled collection microcentrifuge tube.

4.6.2. Repeat this process a total of 4 times using the same pipette tip for all operations.

4.6.3. Repeat the collection process for all other reaction sites on the chip.

5. Synthesis analysis to determine reaction performance and optimal conditions

5.1. Determine the “collection efficiency” for the first reaction on the chip.

5.1.1. Place the microcentrifuge tube with the collected crude product of the first reaction spot in the dose calibrator to measure the activity. Record the measurement and time of the measurement. Repeat this process for each of the collected crude products.

5.1.2. Calculate the collection efficiency by dividing the activity of the collected crude product by the starting activity measured for the same reaction site (decay-correcting the activity values to the same timepoint).

5.1.3. Repeat for all other reaction sites on the chip.

5.2. Analyze the composition (fluorination efficiency) of each collected crude product.

NOTE: To make practical the analysis of all samples in a short time, fluorination efficiency is analyzed using a previously described high-throughput radio-thin layer chromatography (radio-TLC) approach¹⁴. This technique allows up to eight samples to be processed in parallel by spotting then side by side (5 mm pitch, 0.5 μ L per spot) on a single TLC plate, then developing together, and performing readout together using Cerenkov imaging^{14,15}. For the example optimization with 16 parallel reactions, 2 TLC plates are needed. Another option is to use radio- high-performance liquid chromatography (radio-HPLC) for analysis, though the time for separation, cleaning, and equilibration may limit the number of samples that can be analyzed.

5.2.1. For each TLC plate (50 mm x 60 mm), with a pencil, draw a line at 15 mm away from one 50 mm edge (bottom), and another line 50 mm away from the same edge. The first line is the origin line; the second is the solvent front line. Draw 8 small "X"s along the origin line at 5 mm spacing to define the sample spotting position for each of 8 "lanes".

5.2.2. Using a micropipette, transfer 0.5 μ L of the first crude product onto the TLC plate at the "X" for the first lane. Repeat for additional crude products (up to 8 per TLC plate). Wait for the crude product spots to dry on the TLC plate.

5.2.3. For each TLC plate, develop using a mobile phase of 60% MeCN in 25 mM NH_4HCO_2 with 1% TEA (v/v) until the solvent front reaches the solvent front line. Wait for the solvent on the TLC plate to dry and then cover with a glass microscope slide (76.2 mm x 50.8 mm, 1 mm thick).

5.2.4. Obtain a radioactivity image of each TLC plate by placing the plate in a Cerenkov imaging system for a 5 min exposure. Perform standard image corrections (dark current subtraction, flat field correction, median filtering, and background subtraction).

5.2.5. Use region of interest (ROI) analysis for the first lane of the first TLC plate. Draw regions around each band visible in the lane. The software will compute the fraction of integrated intensity of each region (band) compared to the total integrated intensity of all regions (bands).

5.2.6. With this mobile phase, the following bands are expected at the indicated retention factors: $R_f = 0.0$: Unreacted [^{18}F]fluoride; $R_f = 0.9$: [^{18}F]fallypride; $R_f = 0.94$: Side product. Determine the fluorination efficiency as the fraction of activity in the [^{18}F]fallypride band.

5.2.7. Repeat this analysis for all other lanes on all TLC plates.

NOTE: If a Cerenkov imaging chamber is not available, a small animal (preclinical) *in vivo* optical imaging system can be used to image the TLC plates. Alternatively, a 2-dimensional TLC scanner can be used. Alternatively, if only a 1-dimensional TLC scanner is available, the TLC plates can be analyzed by cutting into strips with scissors (1 per lane), and scanning each strip individually.

5.3. Determine the crude radiochemical yield (crude RCY) for each reaction site.

5.3.1. Determine the crude RCY for the first crude product by multiplying the collection efficiency by the fluorination efficiency.

5.3.2. Repeat for all other reaction sites.

5.4. Analyze the results

5.4.1. Aggregate values for any replicate experiments into an average and standard deviation.

5.4.2. Plot the collection efficiency, fluorination efficiency, and crude RCY as a function of the parameter that was varied (precursor concentration in this example).

5.4.3. Select the optimal conditions based on the desired criteria. Typically, this is the maximum crude RCY. Additionally, the point is often chosen in a region where the slope of the graph is relatively flat, indicating it is insensitive to small changes in the parameter, providing a more robust protocol.

REPRESENTATIVE RESULTS:

A representative experiment was performed to illustrate this method. Using 16 reactions, optimization studies of the radiopharmaceutical [^{18}F]fallypride were performed by varying precursor concentration (77, 39, 19, 9.6, 4.8, 2.4, 1.2, and 0.6 mM) in the xyl alcohol:MeCN (1:1, v/v) as the reaction solvent. Reactions were performed at 110 °C for 7 min. Collection efficiency, sample composition (i.e., proportions of [^{18}F]fallypride product, unreacted [^{18}F]fluoride, and side product) are tabulated in **Table 1** and are summarized graphically in **Figure 4**.

The study showed that the fluorination efficiency (proportion of [^{18}F]fallypride) increases with increasing precursor concentration, and that the remaining unreacted [^{18}F]fluoride varied inversely (**Figure 4A**). There was a small amount of a radioactive side product at low precursor concentrations, but the proportion decreased to near zero at the higher precursor concentrations (**Figure 4A**). The collection efficiency was nearly quantitative for most conditions, though it dropped slightly at low precursor concentrations.

From these results, the highest RCY can be achieved with ~230 nmol of precursor (i.e., 39 mM concentration in a 6 μL droplet). At this condition, the fluorination efficiency was $96.0 \pm 0.5\%$ ($n=2$) and the crude RCY was 87.0 ± 2.7 ($n=2$), and there was no observed radioactive side product formation. While the use of 77 mM precursor showed similar results, in general it is desirable to use a lower amount of precursor to reduce cost and simplify downstream purification steps.

FIGURE AND TABLE LEGENDS:

Figure 1: Fabrication of multi-reaction microdroplet chips via photolithography. (A) Photograph of multi-reaction microdroplet chip with 4 x 4 array of reaction sites. The chip consists of polytetrafluoroethylene-coated silicon with circular regions of polytetrafluoroethylene etched

away to create the hydrophilic reaction sites. (B) Schematic of the fabrication procedure. A silicon wafer is spin-coated with Teflon solution and baked to solidify the coating. Next, the photoresist is spin-coated and patterned via photolithography to produce an etch mask. The photoresist is developed with a photoresist developing solution. The exposed Teflon is then removed via dry etching with oxygen plasma. The wafer is diced into individual chips, and the photoresist is stripped.

Figure 2: Procedure for parallel reactions. Experimental procedure for performing 16 parallel syntheses of the radiopharmaceutical [^{18}F]fallypride on a multi-reaction chip. In this example, the precursor concentration is varied for each reaction.

Figure 3: Map of conditions at reaction sites. (A) Experimental design to explore the influence of precursor concentration on the radiofluorination of tosyl fallypride using a single 16-reaction chip (top view). Eight different concentrations were explored, each with $n=2$ replicates. Other reaction conditions were held constant (temperature: 110 °C; time: 7 min; solvent: thexyl alcohol:MeCN; the amount of TBAHCO_3 : 240 nmol). Each reaction was performed with ~ 14 MBq of activity. (B) Photograph of a 16-reaction chip installed on the heater platform during the experiment. Red lines represent the reference corner of the chip used for alignment with the reference corner of the heater.

Figure 4: Influence of precursor concentration on the microdroplet synthesis of [^{18}F]fallypride. (A) Proportion of radioactive species present in the collected crude reaction product, i.e. [^{18}F]fallypride, side product, or unreacted [^{18}F]fluoride. (B) Synthesis performance. Collection efficiency, fluorination efficiency, and crude RCY are plotted as a function of precursor concentration. In both graphs, data points represent the average of $n=2$ replicates, and error bars represent the standard deviation.

Table 1: Data obtained from study of precursor concentration. All values are averages \pm standard deviations computed from $n=2$ replicates.

DISCUSSION:

Due to limitations of conventional radiochemistry systems that allow only one or a small number of reactions per day and consume a significant quantity of reagents per data point, only a tiny portion of the overall reaction parameter space can be explored in practice, and many times results are reported with no repeats ($n=1$). Compared to conventional systems, this multi-reaction droplet radiosynthesis platform makes it practical to accomplish more comprehensive and rigorous studies of radiosynthesis conditions while consuming very little time and amount of precursor, potentially enabling new insights on parameters that impact product yield and side-product formation. The information can be used to choose the conditions that result in the highest product yield or the most robust synthesis. The low precursor consumption may be especially useful in the early development of novel radiotracers when only a small amount of precursor may be available or when the precursor is expensive. While the open nature of the chips contributes to rapid synthesis time and ease of access via pipette, it can lead to substantial losses of volatile molecules and may not be practical when optimizing the synthesis of

radiopharmaceuticals that have volatile precursors, intermediates, or products.

Due to the hazard of radiation exposure, it should be reiterated that these experiments should be performed only with suitable training and approvals and should be conducted behind radiation shielding, preferably in a ventilated hot cell. Due to the short half-life of the radioisotopes, it is important to perform the experiments quickly and efficiently. Pipetting reagents to the chip and collecting products from the chip should be practiced under non-radioactive conditions to become familiar with the reduced access and visibility in a hot cell. Similarly, installing and removing the chip, and making measurements of the chip with the dose calibrator should also be practiced. In addition, it is critical to be organized, with a detailed experiment map (i.e., specific reaction conditions at each site on the chip). It is also helpful to prepare in advance a table of results to be filled in as measurements are made. To ensure reproducibility, especially with the possibility of human error, multiple replicates of each set of conditions should be performed. It is important to be especially careful during the step of collecting the crude samples from the chip to avoid spilling liquid outside the reaction site and causing cross-contamination with adjacent reaction sites. If any errors are noticed, it is important to flag these reaction sites so the data can be excluded from the eventual analysis.

In this example study, the amount precursor consumed for 16 data points was 1.1 mg (~70 μ g each), compared to 4 mg per data point using a conventional radiosynthesizer. Furthermore, all 16 reactions were completed in 25 min all in a single experiment. In comparison, the synthesis of crude [18 F]fallypride on a conventional radiosynthesizer requires ~15-20 min per reaction^{16, 17}.

This representative experiment demonstrated the utility of a multi-reaction microdroplet chip with 16 reactions to optimize conditions for the radiosynthesis of the radiopharmaceutical [18 F]fallypride by exploring 8 different precursor concentrations (n=2 replicates for each condition) in a fast and economical manner. Other variables that can be conveniently optimized using a multi-reaction chip include the amount of radioactivity, type of phase transfer catalyst, amount of phase transfer catalyst, evaporation/drying conditions (e.g., number of azeotropic drying steps), reaction solvent, etc. By using multiple multi-reaction chips, it also is possible to explore the influence of reaction temperature and reaction time, in addition to conditions such as evaporation/drying temperature and time. Such studies would need to be performed sequentially using the single heater or could be parallelized by operating multiple heaters at the same time.

The underlying droplet synthesis method has been shown to be compatible with a wide range of 18 F-labeled radiopharmaceuticals, such as [18 F]fallypride¹⁰, [18 F]FET¹⁸, [18 F]FDOPA¹⁹, [18 F]FBB²⁰ and it can be used for the optimization of the majority of other 18 F-labeled compounds and compounds labeled with other isotopes. Moreover, the resulting optimized droplet-based reactions intrinsically leverage the advantages of microvolume radiochemistry, including reduced precursor consumption, faster process times, and compact instrumentation, and can offer these same advantages for routine production of large batches. Larger batches simply require scaling up the amount of activity initially loaded at the start of the reaction. To prepare a tracer suitable for use in in vitro or in vivo assays, the crude product must be purified (e.g., using analytical-scale

HPLC) and formulated (e.g. via evaporative or solid-phase solvent exchange²¹) Alternatively, it may be possible to adapt the optimal conditions from droplet-scale to a conventional vial-based radiosynthesizer. Investigation of this possibility is ongoing.

ACKNOWLEDGMENTS:

We thank the UCLA Biomedical Cyclotron Facility and Dr. Roger Slavik and Dr. Giuseppe Carlucci for generously providing [¹⁸F]fluoride for these studies and the UCLA NanoLab for support with equipment for chip fabrication.

DISCLOSURES:

The Regents of the University of California have licensed technology to Sofie, Inc. that was invented by Dr. van Dam, and have taken equity in Sofie, Inc. as part of the licensing transaction. Dr. van Dam is a founder and consultant of Sofie, Inc. The remaining authors declare no conflicts of interest. This work was supported in part by the National Cancer Institute (R33 240201).

REFERENCES:

1. Matthews, P. M., Rabiner, E. A., Passchier, J., Gunn, R. N. Positron emission tomography molecular imaging for drug development. *British Journal of Clinical Pharmacology*. **73** (2), 175–186 (2012).
2. Piel, M., Vernaleken, I., Rösch, F. Positron emission tomography in CNS drug discovery and drug monitoring. *Journal of Medicinal Chemistry*. **57** (22), 9232–9258 (2014).
3. Cherry, S. R., Sorenson, J. A., Phelps, M. E. *Physics in Nuclear Medicine*. Elsevier Saunders. Philadelphia, PA, USA. (2012).
4. Knapp, K. -A., Nickels, M. L., Manning, H. C. The current role of microfluidics in radiofluorination chemistry. *Molecular Imaging and Biology*. **22** (3), 463–475 (2020).
5. Rensch, C. et al. Microfluidics: A groundbreaking technology for PET tracer production? *Molecules*. **18** (7), 7930–7956 (2013).
6. Pascali, G., Watts, P., Salvadori, P. A. Microfluidics in radiopharmaceutical chemistry. *Nuclear Medicine and Biology*. **40** (6), 776–787 (2013).
7. Keng, P. Y., van Dam, R. M. Digital microfluidics: A new paradigm for radiochemistry. *Molecular Imaging*. **14**, 579–594 (2015).
8. Wang, J., Chao, P. H., Janet, S., van Dam, R. M. Performing multi-step chemical reactions in microliter-sized droplets by leveraging a simple passive transport mechanism. *Lab on a Chip*. **17** (24), 4342–4355 (2017).
9. Wang, J., Chao, P. H., van Dam, R. M. Ultra-compact, automated microdroplet radiosynthesizer. *Lab on a Chip*. (19), 2415–2424 (2019).
10. Rios, A., Wang, J., Chao, P. H., van Dam, R. M. A novel multi-reaction microdroplet platform for rapid radiochemistry optimization. *RSC Advances*. **9** (35), 20370–20374 (2019).
11. Sergeev, M. et al. Performing radiosynthesis in microvolumes to maximize molar activity of tracers for positron emission tomography. *Communications Chemistry*. **1** (1), 10 (2018).
12. Pascali, G. et al. Optimization of nucleophilic ¹⁸F radiofluorinations using a microfluidic reaction approach. *Nature Protocols*. **9** (9), 2017–2029 (2014).
13. Lisova, K. et al. Microscale radiosynthesis, preclinical imaging and dosimetry study of [¹⁸F]AMBF3-TATE: A potential PET tracer for clinical imaging of somatostatin receptors. *Nuclear*

Medicine and Biology. **61**, 36–44 (2018).

14. Wang, J. et al. High-throughput radio-TLC analysis. *Nuclear Medicine and Biology*. **82–83**, 41–48 (2020).

15. Dooraghi, A. A. et al. Optimization of microfluidic PET tracer synthesis with Cerenkov imaging. *Analyst*. **138** (19), 5654–5664 (2013).

16. Collins, J. et al. Production of diverse PET probes with limited resources: 24 ¹⁸F-labeled compounds prepared with a single radiosynthesizer. *Proceedings of the National Academy of Sciences*. **114** (43), 11309–11314 (2017).

17. Lazari, M. et al. Fully automated production of diverse ¹⁸F-labeled PET tracers on the ELIXYS multireactor radiosynthesizer without hardware modification. *Journal of Nuclear Medicine Technology*. **42** (3), 203–210 (2014).

18. Lisova, K. et al. Rapid, efficient, and economical synthesis of PET tracers in a droplet microreactor: application to O-(2-[¹⁸F]fluoroethyl)-L-tyrosine ([¹⁸F]FET). *EJNMMI Radiopharmacy and Chemistry*. **5** (1), 1 (2019).

19. Wang, J., Holloway, T., Lisova, K., van Dam, R. M. Green and efficient synthesis of the radiopharmaceutical [¹⁸F]FDOPA using a microdroplet reactor. *Reaction Chemistry & Engineering*. **5** (2), 320–329 (2020).

20. Lisova, K., Wang, J., Rios, A., van Dam, R. M. Adaptation and optimization of [¹⁸F]Florbetaben ([¹⁸F] FBB) radiosynthesis to a microdroplet reactor. *Journal of Labelled Compounds and Radiopharmaceuticals*. **62**, S353–S354 (2019).

21. Wang, J., Chao, P. H., Slavik, R., Dam, R. M. van Multi-GBq production of the radiotracer [¹⁸F]fallypride in a droplet microreactor. *RSC Advances*. **10** (13), 7828–7838 (2020).





Figure 2








Figure 4



Precursor concertation (mM)	Collection efficiency (%)	Fluorination efficiency (%)	Crude RCY (%)
77	91.8 ± 2.1	96.7 ± 2.0	88.8 ± 3.9
39	90.6 ± 2.4	96.0 ± 0.5	87.0 ± 2.7
19	91.1 ± 0.5	81.1 ± 0.3	73.9 ± 0.7
9.6	90.9 ± 0.6	62.7 ± 0.9	57.0 ± 0.5
4.8	88.4 ± 0.8	37.0 ± 1.5	32.8 ± 1.6
2.4	87.6 ± 2.0	21.0 ± 2.1	18.4 ± 2.2
1.2	82.3 ± 1.6	12.7 ± 0.3	10.4 ± 0.1
0.6	81.2 ± 3.7	6.3 ± 0.8	5.1 ± 0.5

Unreacted [^{18}F]fluoride (%)	Side product (%)
3.3 ± 2.0	0.0 ± 0.0
4.0 ± 0.5	0.0 ± 0.0
8.4 ± 1.2	10.5 ± 2.0
23.3 ± 2.1	14.0 ± 0.9
47.3 ± 0.8	15.7 ± 1.0
67.4 ± 2.1	11.6 ± 1.0
72.8 ± 0.7	14.5 ± 1.0
84.3 ± 0.2	9.4 ± 1.0

Name of Material/ Equipment	Company	Catalog Number
2,3-dimethyl-2-butanol (thexyl alcohol)	Sigma-Aldrich	594-60-5
Acetone	KMG Chemicals	
Ammonium formate (NH ₄ HCO ₂)	Sigma-Aldrich	540-69-2
Anhydrous acetonitrile (MeCN)	Sigma-Aldrich	75-05-8
Ceramic heater	Watlow	Utramic CER-1-01-0093
Cerenkov imaging chamber	Custom built	
DI water	Sigma-Aldrich	7732-18-5
Disposable transfer pipets, 3 mL	Falcon	13-680-50
Dose calibrator	Capintec, Inc.	CRC-25 PET
Fallypride	ABX Advanced Biochemical Compounds	1560.0010.000
[¹⁸ F]fluoride in [¹⁸ O]H ₂ O	UCLA Ahmanson Biomedical Cyclotron Facility	
Glass cover plates (76.2 mm x 50.8 mm x 1 mm thick)	C&A Scientific	6101
Headway spin coater	Headway Research, Inc.	PWM50-PS-R790
High temperature oven	Carbolite	Sipinner system
Hot plate	Thermo Scientific	HTCR 6 28
Isopropanol (IPA)	KMG Chemicals	Super-Nuova
Mask aligner	Karl Suss	HP133425
Methanol (MeOH)	Sigma-Aldrich	MA/BA6
Microcentrifuge tube	Eppendorf	67-56-1
Micropipette (0.5-10 µL)	Labnet	0030 123.301
		BioPette P3940-10

Micropipette (100-1000 µL)	Labnet	BioPette P3940-1000
Micropipette (10-100 µL)	Labnet	BioPette P3940-100
Micropipette tips (0.1-10 µL)	USA Scientific Inc Tips	11113810
Micropipette tips (2-200 µL)	BrandTech	13-889-143
Micropipette tips (50-1000 µL)	BrandTech	13-889-145
Photoresist developer solution	MicroChem	MEGAPOSIT MF-26A
Positive photoresist	MicroChem	MEGAPOSIT 220-7.0
Reactive-ion etcher (RIE)	Oxford Instruments	Plasma Lab 80 Plus
Silicon wafer cutter	Euro Tool	CSCB-431.00
Silicon wafer; 4" diameter	Silicon Valley Microelectronics Inc.	0017227-048
Teflon AF 2400	Chemours	D14896765
Tetrabutylammonium bicarbonate (TBAHCO ₃)	ABX Advanced Biochemical Compounds	808
Thermal conducting paste	OMEGA	OT-201-2
TLC plates	Merck KGaA	1.05554.0001
Tosyl-fallypride	ABX Advanced Biochemical Compounds	1550.004.000
Trimethylamine (TEA)	Sigma-Aldrich	75-50-3
Tweezers	Cole-Parmer	UX-07387-08

Comments/Description

98%

Cleanroom LP grade

97%

99.80%

25 mm x 25 mm

Other instruments can be used for TLC plate readout including: small animal *in vivo* optical imaging system,
2D radio-TLC scanner, 1D radio-TLC scanner

Fallypride reference standard, >95%

Due to short half-life this must be obtained from local radiochemistry lab or commercial radiopharmacy

PWM50-control box, PS-motor, R790-bowl

Cleanroom LP grade

≥99.9%

500 µL, colorless, polypropylene

P type, boron doped, thickness $525 \pm 25 \mu\text{m}$
1% solids

Aqueous solution stabilized with ethanol, 0.075 M

Silica gel 60 F₂₅₄, 50 mm x 60 mm, aluminum back
Fallypride precursor, >90%
≥ 99%
Stainless steel, fine tip

Response to Reviewer Comments

We appreciate the time and effort of the editor and reviewers to review our manuscript. The helpful comments and suggestions have led to important improvements in the manuscript. We provide below a point by point response to each comment. The original comments are in black text and our responses are in green text.

Editorial comments:

Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues. Please define all abbreviations at first use.

We have carefully checked spelling, grammar, and abbreviations.

Please provide an email address for each author.

We have provided an email address for each author in the online submission system.

Unfortunately, there are sections of the manuscript that show overlap with previously published work. Please revise the following lines: Discussion lines 364-368 (...formation)

We have revised this portion of the discussion to differentiate from previously published work.

JoVE cannot publish manuscripts containing commercial language. This includes trademark symbols (™), registered symbols (®), and company names before an instrument or reagent. Please remove all commercial language from your manuscript and use generic terms instead. All commercial products should be sufficiently referenced in the Table of Materials and Reagents. For example: Teflon AF 2400, HTCR 6 28, Carbolite; SPR 220-7, MA6, Karl Suss, MF-26A, Oxford80 Plus RIE, Eppendorf tube, etc

We have removed the trademark etc. symbols, and have remove the product names/models from the main paper and moved into the materials list. We have left “Teflon” in the paper due to its ubiquitous use; if this is not acceptable, it can be changed to “perfluoropolymer”

Please revise the protocol text to avoid the use of any personal pronouns (e.g., "we", "you", "our" etc.).

We have removed all personal pronouns.

Please ensure that all text in the protocol section is written in the imperative tense as if telling someone how to do the technique (e.g., “Do this,” “Ensure that,” etc.). The actions should be described in the imperative tense in complete sentences wherever possible. Avoid usage of phrases such as “could be,” “should be,” and “would be” throughout the Protocol. Any text that cannot be written in the imperative tense may be added as a “Note.” However, notes should be concise and used sparingly. Please include all safety procedures and use of hoods, etc.

We have checked the protocol section and corrected to ensure we are using imperative tense everywhere.

Please note that your protocol will be used to generate the script for the video and must contain everything that you would like shown in the video. Please add more details to your protocol steps. Please ensure you answer the “how” question, i.e., how is the step performed? Alternatively, add references to published material specifying how to perform the protocol action. Please add more specific details (e.g. button clicks for software actions, numerical values for settings, etc) to your protocol steps. There should

be enough detail in each step to supplement the actions seen in the video so that viewers can easily replicate the protocol.

We have added more details to each step.

Line 154: Are you using glass vials or Eppendorf tubes?

We are using Eppendorf tubes. We have removed mention of vials and use the term microcentrifuge tubes for clarity.

Please check all chemical formulae, e.g., line 242: do you mean NH_4HCO_3 ?

We checked this and the original version is correct, NH_4HCO_2 .

After including a one-line space between each protocol step, highlight up to 3 pages of protocol text for inclusion in the protocol section of the video. This will clarify what needs to be filmed.

We checked the highlighted portions of the manuscript and made few changes to fit the highlighted protocol text in 3 pages with a one-line space in between each protocol step.

As we are a methods journal, please add to the discussion any critical steps within the protocol, modifications and troubleshooting of the technique, limitations of the technique.

We have added some additional elements to the discussion.

Please submit each figure individually as a vector image file to ensure high resolution throughout production: (.psd, ai, .eps.). Please remove the embedded figure(s) from the manuscript. Figure legends (titles and description) should appear after the Representative Results of the manuscript text.

We removed the figures and consolidate captions in the place indicated.

Please remove the embedded Table from the manuscript. All tables should be uploaded separately to your Editorial Manager account in the form of an .xls or .xlsx file. Table captions (title and description) should after the Representative Results of the manuscript text.

We removed the table and consolidated the caption in the place indicated.

Please sort the Materials Table alphabetically by the name of the material.

We have sorted it.

Reviewer 1 Comments:

Please make sure to use the latest nomenclature guided from SRS.

We have checked carefully and believe we are using the correct nomenclature.

In order to ensure the safest process, is there an indication on the need (or not) of active ventilation/extraction during the execution of these experiments?

We appreciate the reviewer's question; we have clarified this at the beginning of the Protocol section.

In order to gauge robustness of the process, how does the data compare among different days or different chips?

We thank the reviewer for the insightful question. To assess robustness of the process when we perform experiments in different days and different chips, we include a few data points with identical conditions to the previous day as a reference point. From our recent work in *RSC Adv.*, 2019,9, 20370-20374, the following are some examples of these replicated conditions to give an idea of repeatability:

Set 1 (Reaction conditions: 240 nmol of TBAHCO₃ with a 4 μ L droplet solution of 77 mM of precursor):

Performance measurement	Day 1 (n=2)	Day 2 (n=2)
Collection efficiency (%)	94 \pm 1	92 \pm 1
Fluorination efficiency (%)	98.9 \pm 0.2	96 \pm 1

Set 2 (Reaction conditions: 240 nmol of TBAHCO₃ with a 6 μ L droplet solution of 77 mM of precursor):

Performance measurement	Day 2 (n=2)	Day 3 (n=2)
Collection efficiency (%)	92 \pm 1	92 \pm 2
Fluorination efficiency (%)	98 \pm 1	97 \pm 2

Can the authors comment whether or how this data can be used to transfer the process into a “full-batch” synthesis, comprising purification, formulation and higher starting activities?

We thank the reviewer for the interesting question. One approach is to scale up the activity in a droplet and do a ‘full-batch’ synthesis under the same droplet conditions as found by the optimization study, and perform purification by analytical-scale radio-HPLC and formulation using evaporation or cartridge methods. We’ve previously reported scale-up of [¹⁸F]fallypride to 41 GBq starting activity *RSC Adv.*, 2020,10, 7828-7838, followed by purification, formulation, and quality control testing. We have added a note to this effect at the end of the Discussion section.

We plan to study in the future the possibility to adapt the conditions to the macroscale. After choosing a suitable reaction volume (e.g. 1 mL), a good starting point may be to preserve the same precursor concentration and calculate the amount of base to preserve the base:precursor ratio. Temperature can be kept the same, but likely a longer reaction time will be needed, as it can take many minutes for the reactor contents to reach the desired temperature.

It took that all additions/handling is done manually (e.g. pipette). Is it possible to automate these tasks? Can the authors comment on what would be difference in using multi-well automated synthesizer robots?

Even based on new concepts,
<https://pubs.rsc.org/en/content/articlelanding/2019/lc/c9lc00622b#!divAbstract>

To increase safety and reduce tedious work, we are currently working on automation. We have developed a custom system (to fit in a mini-cell and using very fast motors to minimize decay) to dispensing various reagents, collecting products, etc. Publication of the system will be forthcoming, but some details can be found in the following abstract from ISRS 2019:

Jones, J.; Rios, A.; Chao, P.; Wang, J.; van Dam, R. M. High-Throughput Microdroplet Radiochemistry Platform to Accelerate Radiotracer Development. In *Journal of Labelled Compounds & Radiopharmaceuticals*; 2019; Vol. 62, pp S350–S351.

We thank the reviewer for the interesting paper. Our automated platform uses non-contact piezoelectric dispensers, but we are very interested in switching to a lower-cost dispensable dispenser approach in the future.

Minor comments:

Please edit the text for grammar and syntax, there is sometimes a little tendency to repeat the same word at short distance.

We have checked the grammar and syntax, and also removed any duplicated words.

Why the yellow highlight?

The yellow highlight is requested by the journal to indicate the portions of the manuscript to be used for the narrative script in the protocol video.

In the text, it is not clear how to measure the starting activity with dose calibrator

We thank the reviewer for pointing out this issue. We first start by loading activity to the first reaction site on the chip and measure the chip with a dose calibrator and record the time at which the measurement was conducted. We then load activity to the second reaction site and perform another dose calibrator measurement, taking the difference between the new measurement and previous measurement as the amount of activity loaded for the second reaction (corrected for decay). The process is repeated for all sites. We have modified the text to clarify this.

Line242: “NH₄HCO₃”?

Our original text NH₄HCO₂ is the intended formula.

Line 258: or using HPLC? I believe such method cannot be forgotten to be proposed as an option

Yes, we agree! We have added a statement to the end of the note at the beginning of Protocol step 2.

What is the total time for each 16 reactions run, from radioactivity bulk delivery to obtaining all the TLC results? It is said 25 min, but it is not clear when the “stopwatch” is started and stopped.

We thank the reviewer for question. The stopwatch starts when we first load the [¹⁸F]fluoride mixed with the base / phase transfer catalyst to the first reaction spot on the chip and the stopwatch is stopped when we measure the last crude product that is extracted from the chip. The TLC results can be obtained in 10 additional minutes.

Is it possible or suggestible to use DoE approaches to setup the conditions to be tested? This approach would allow for this; however, given the difficulty to have an “online” analysis method, it still would not be useful to achieve an automated optimization (e.g. using feedback algorithms).

We thank the reviewer for the useful comment. Certainly we believe the platform can be used in conjunction with DoE design approaches, though they might need to be somewhat constrained to efficiently make use of parallelism. (E.g. if all conditions had different temperature or reaction time, they would have to be performed sequentially.) We are very interested in exploring this in the future. Furthermore, we are currently working on a platform that can allow the performance of 64 simultaneous

reactions and adds parallelism in the temperature and time parameters to further facilitate parallel optimization.

The reviewer is correct that we lack an online analysis method and cannot currently doing automated optimization. We are not sure how to best combine some amount of parallelism with automated selection of the next set of conditions, but this is an interesting challenging for the future!

Reviewer 2 Comments:

In my idea it could be published without revision

We thank the reviewer for their very positive assessment of our manuscript.

Reviewer 3 Comments:

Abstract line 28-30. "These chips enable enables rapid and convenient studies of reaction parameters including reagent concentrations and reaction solvent, and the use of multiple chips enables the study of reaction temperature and time". The reaction parameters contain the reaction temperature and time. So, I think it. would be good to write the contents of multi-chips concisely in one sentence as follow. "These chips enable rapid and convenient studies of reaction parameters including reagent concentrations, reaction solvent, temperature and time."

We thank the reviewer for the useful comment. We had originally separate it because a single chip cannot efficiently explore different temperature or times, and it takes multiple chips to explore those variables with parallelism. However, we agree that this reads better in the suggested form.

Uniform the style. In vivo -> *in vivo* (italic), [18F]Fallypride -> [18F]fallypride

We thank the reviewer for the useful comment, and we changed the style as suggested in the manuscript.

Introduction line 38-41. Due to the short half-life of these molecules -> Due to the short half-life of radioisotopes.

We have modified as suggested.

Tracer -> radiotracer

We have made the suggested change.

"because multiple patient scans and research experiments can be scheduled at the same time"
At the same time -> in a single day

Thank you for the suggestion, we have made this change.

Line 75-77. "Using multi-reaction droplet chips allows for convenient exploration of the impact of reagent concentrations and reaction solvent, and the use of multiple chips could enable the study of reaction temperature and time, all while consuming very low amounts of precursor"
I want to change the sentence to be concise like the above my minor concern

We thank the reviewer for the comment. We have elected to leave the original text because we feel here the distinction between what can be done on one chip is distinct from what can be explored with multiple chips. Since the whole chip is heated at once, all reactions performed simultaneously must be performed at the same temperature and reaction time. Multiple different chips (and heaters) are needed to explore different temperatures or reaction times in parallel. If the reviewer feels strongly about this point, we can modify as suggested.

UNIVERSITY OF CALIFORNIA, LOS ANGELES

UCLA

BERKELEY • DAVIS • IRVINE • LOS ANGELES • RIVERSIDE • SAN DIEGO • SAN FRANCISCO

SANTA BARBARA • SANTA CRUZ

R. MICHAEL VAN DAM, PH.D.
PROFESSORDEPARTMENT OF MOLECULAR AND MEDICAL PHARMACOLOGY
CRUMP INSTITUTE FOR MOLECULAR IMAGING
DAVID GEFLEN SCHOOL OF MEDICINE AT UCLACALIFORNIA NANOSYSTEMS INSTITUTE, ROOM 4323
570 WESTWOOD PLAZA
LOS ANGELES, CALIFORNIA 90095-7227(310) 206-6507
E-MAIL: MVANDAM@MEDNET.UCLA.EDUAugust 12th, 2020Dr. Rafaela Vasiliadou
Guest Editor, Journal of Visualized Experiments
School of Life, Health, and Chemical Sciences
Open University
UK

Dear Dr. Vasiliadou,

Please find attached our manuscript entitled “Rapid and economical optimization of radiochemical reactions using droplet arrays”, which we respectfully submit for the upcoming special collection “Miniaturization of biochemical and chemical techniques” in the *Journal of Visualized Experiments*. The full author list includes: Alejandra Rios, Travis H. Holloway, Jia Wang, and R. Michael van Dam (corresponding author).

In this paper, we describe a new method for economical high-throughput synthesis optimization of positron-emission tomography (PET) radiopharmaceuticals. Due to the unique challenges in this field (radiation hazard, short half-life of radioisotopes), synthesis of these compounds is usually carried out in an automated fashion using “radiosynthesizers”. These systems, however, are designed for producing large batches and can only be used on an occasional basis (i.e. typically one waits ~10 half-lives (i.e., 18 hours if using fluorine-18 with 109.8 min half-life) to allow residual radioactivity to decay to background levels before the system can be used again. As a result, optimization experiments are very costly and time-consuming, and only a tiny fraction of the available parameter space can be explored. Instead, we developed a multi-reaction microdroplet chip that contains an array of reaction sites for performing 16 simultaneous droplet-based radiochemical reactions. Each reaction uses minimal reagents and radioisotope, and the timeline and costs for optimization can be compressed 10-fold or more.

Using the synthesis of [¹⁸F]Fallypride (a clinically-relevant PET tracer for visualizing D2/D3 receptors in the brain) as an example, we show how this technique is used to optimize one of several synthesis parameters, namely the precursor concentration. The ability to perform 16 reactions in 25 min allowed the optimization to be completed much more quickly than would be

possible using a conventional synthesizer. We believe this approach will be a valuable tool in the field of radiochemistry to accelerate synthesis optimization and to enable the study of reaction conditions in far greater detail than is currently practical. Moreover, the resulting optimized droplet-based reactions intrinsically leverage the advantages of microvolume radiochemistry, including reduced precursor consumption, faster process times, and compact instrumentation, and can offer these same advantages even for routine production of larger batches.

We believe that this work will be of broad interest to readers and viewers of *Journal of Visualized Experiments*, and will be of particular interest to those in the fields of radiochemistry and nuclear medicine (especially those developing new radiotracers, those developing new radiosynthesis/radiolabeling methods, and those developing, optimizing, and translating radiosynthesis protocols into the clinic).

Thank you for considering this manuscript and we look forward to your response.

Sincerely,

A handwritten signature in grey ink, appearing to read 'Michael - e', with a long horizontal flourish extending to the right.

R. Michael van Dam, Ph.D.

Professor, Department of Molecular & Medical Pharmacology
Co-Associate Director, Crump Institute for Molecular Imaging
David Geffen School of Medicine at UCLA